{"id":528420,"date":"2017-09-05T20:05:00","date_gmt":"2017-09-05T20:05:00","guid":{"rendered":"https:\/\/www.pm360online.com\/?guid=8dda8a128978febb95a6098408c47997"},"modified":"2017-09-05T20:05:00","modified_gmt":"2017-09-05T20:05:00","slug":"horizon-pharma-plc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2","status":"publish","type":"post","link":"https:\/\/www.pm360online.com\/horizon-pharma-plc-reports-inducement-grants-under-nasdaq-listing-rule-5635c4-2\/","title":{"rendered":"Horizon Pharma plc Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)"},"content":{"rendered":"

DUBLIN, Ireland, Sept. 05, 2017 (GLOBE NEWSWIRE) — Horizon Pharma plc (NASDAQ:HZNP<\/a>), a biopharmaceutical company focused on improving patients\u2019 lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on Sept. 1, 2017 of inducement restricted stock units for an aggregate of 227,073 shares of common stock to 52 new employees.<\/p>\n

Each restricted stock unit vests over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employee’s continued service relationship with the Company. \u00a0Each restricted stock unit also is subject to the terms and conditions of the Company’s 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.<\/p>\n

The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).<\/p>\n

About Horizon Pharma plc<\/em><\/strong>
Horizon Pharma plc is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.\u00a0 The Company markets 11 medicines through its orphan, rheumatology and primary care business units.\u00a0 For more information, please visit www.horizonpharma.com<\/a>.\u00a0 Follow @HZNPplc on Twitter or view careers on our LinkedIn page.<\/p>\n

\u00a0<\/p>\n

CONTACT: Contacts:\nTina Ventura\nSenior Vice President, Investor Relations\nInvestor-relations@horizonpharma.com\n\nRuth Venning\nExecutive Director, Investor Relations\nInvestor-relations@horizonpharma.com\n\nU.S. Media Contact:\nGeoffrey Curtis\nSenior Vice President, Corporate Affairs and Chief Communications Officer\nmedia@horizonpharma.com\n\nIreland Media Contact:\nRay Gordon\nGordon MRM\u00a0\nray@gordonmrm.ie<\/pre>\n","protected":false},"excerpt":{"rendered":"
DUBLIN, Ireland, Sept.  05, 2017  (GLOBE NEWSWIRE) — Horizon Pharma plc (NASDAQ:HZNP<\/a>), a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today announced that the compensation committee of its board of directors approved the grant on Sept. 1, 2017 of inducement restricted stock units for an aggregate of 227,073 shares of common stock to 52 new employees.<\/p>\n
Each restricted stock unit vests over four years, with 25 percent of the shares vesting on each anniversary of the applicable vesting commencement date, subject to the new employee’s continued service relationship with the Company.  Each restricted stock unit also is subject to the terms and conditions of the Company’s 2014 Equity Incentive Plan and the restricted stock unit agreement pursuant to which the restricted stock unit was granted.<\/p>\n
The restricted stock units were granted as inducements material to the new employees entering into employment with Horizon Pharma in accordance with NASDAQ Listing Rule 5635(c)(4).<\/p>\n
About Horizon Pharma plc<\/em><\/strong>
Horizon Pharma plc is a biopharmaceutical company focused on improving patients’ lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs.  The Company markets 11 medicines through its orphan, rheumatology and primary care business units.  For more information, please visit www.horizonpharma.com<\/a>.  Follow @HZNPplc on Twitter or view careers on our LinkedIn page.<\/p>\n
 <\/p>\n
CONTACT: Contacts:\nTina Ventura\nSenior Vice President, Investor Relations\nInvestor-relations@horizonpharma.com\n\nRuth Venning\nExecutive Director, Investor Relations\nInvestor-relations@horizonpharma.com\n\nU.S. Media Contact:\nGeoffrey Curtis\nSenior Vice President, Corporate Affairs and Chief Communications Officer\nmedia@horizonpharma.com\n\nIreland Media Contact:\nRay Gordon\nGordon MRM \nray@gordonmrm.ie<\/pre>\n","protected":false},"author":74553,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[71350,71364],"tags":[],"_links":{"self":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/528420"}],"collection":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/users\/74553"}],"replies":[{"embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/comments?post=528420"}],"version-history":[{"count":0,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/posts\/528420\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/media?parent=528420"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/categories?post=528420"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.pm360online.com\/wp-json\/wp\/v2\/tags?post=528420"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}